SAFETY AND EFFICACY ANALYSIS OF ENOXAPARIN VERSUS RIVAROXABAN AFTER TOTAL HIP OR KNEE ARTHROPLASTY: META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
Author(s)
Gebrehiwet P1, Rane A1, Pande A1, Doucette J1, Eguale T2
1MCPHS University, Boston, MA, USA, 2MCPHS University, Brookline, MA, USA
Ten studies were included in the meta-analysis. Compared to rivaroxaban, enoxaparin had a higher risk of liver injury [RR= 1.77; 95% CI: 1.29,2.44]. Use of enoxaparin resulted in a nearly two-fold risk for DVT compared to rivaroxaban and was statistically significant. The pooled estimate for proximal DVT, distal DVT and any DVT were [RR=3.04; 95% CI: 1.34,6.88], [RR=1.72; 95% CI: 1.29,2.29], [RR=2.09; 95% CI :1.48,2.97] respectively. However, there was no statistically significant difference in the rate of symptomatic and asymptomatic DVT, PE, mortality, and bleeding between the two drugs.
CONCLUSIONSEnoxaparin was associated with a higher risk for liver injury and rivaroxaban was associated with lower rates of distal DVT, proximal DVT, and any DVT. However, no difference was observed in the risk of bleeding, PE, and mortality. Overall, enoxaparin is less effective and more risky compared to rivaroxaban for people undergoing total knee or hip arthroplasty.
Conference/Value in Health Info
Value in Health, Volume 23, Issue 5, S1 (May 2020)
Code
PSU11
Topic
Clinical Outcomes
Topic Subcategory
Clinical Outcomes Assessment, Comparative Effectiveness or Efficacy
Disease
Drugs, Injury and Trauma, Surgery